Abstract
Continuous-flow left ventricular assist devices (CF LVAD) are increasingly used in the therapeutic algorithm for patients with end-stage heart failure (HF). Treated patients show improvements on global health status measures. However, there has been limited investigation regarding the prevalence and
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
